NovoPro
Cart 2
  • TGFB2 Polyclonal Antibody

TGFB2 Polyclonal Antibody

Cat.#: 164170

Special Price 174.2 USD

Availability: In Stock
- +

Add to cart to get an online quotation

Product Information

  • Product Name
    TGFB2 Polyclonal Antibody
  • Documents
  • Description
    Polyclonal antibody to TGFB2
  • Tested applications
    WB, IF
  • Species reactivity
    Human, Mouse, Rat
  • Alternative names
    TGFB2 antibody; G-TSF antibody; LDS4 antibody; TGF-beta2 antibody; transforming growth factor beta-2 antibody
  • Isotype
    Rabbit IgG
  • Preparation
    Antigen: Recombinant fusion protein containing a sequence corresponding to amino acids 20-160 of human TGFB2 (NP_001129071.1).
  • Clonality
    Polyclonal
  • Formulation
    PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
  • Storage instructions
    Store at -20℃. Avoid freeze / thaw cycles.
  • Applications
    WB 1:200 - 1:2000
    IF 1:50 - 1:200
  • Validations

    Western blot - TGFB2 Polyclonal Antibody

    Western blot - TGFB2 Polyclonal Antibody

    Western blot analysis of extracts of various cell lines, using TGFB2 antibody at 1:1000 dilution.Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution.Lysates/proteins: 25ug per lane.Blocking buffer: 3% nonfat dry milk in TBST.Detection: ECL Basic Kit .Exposure time: 30s.

  • Background
    Transforming growth factor beta-2 proprotein: Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-2 (TGF-beta-2) chains, which constitute the regulatory and active subunit of TGF-beta-2, respectively.; Latency-associated peptide: Required to maintain the Transforming growth factor beta-2 (TGF-beta-2) chain in a latent state during storage in extracellular matrix (By similarity). Associates non-covalently with TGF-beta-2 and regulates its activation via interaction with 'milieu molecules', such as LTBP1 and LRRC32/GARP, that control activation of TGF-beta-2 (By similarity).; Transforming growth factor beta-2: Multifunctional protein that regulates various processes such as angiogenesis and heart development. Activation into mature form follows different steps: following cleavage of the proprotein in the Golgi apparatus, Latency-associated peptide (LAP) and Transforming growth factor beta-2 (TGF-beta-2) chains remain non-covalently linked rendering TGF-beta-2 inactive during storage in extracellular matrix (By similarity). At the same time, LAP chain interacts with 'milieu molecules', such as LTBP1 and LRRC32/GARP, that control activation of TGF-beta-2 and maintain it in a latent state during storage in extracellular milieus (By similarity). Once activated following release of LAP, TGF-beta-2 acts by binding to TGF-beta receptors (TGFBR1 and TGFBR2), which transduce signal (By similarity).
  • References

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"